Clinical trials: Differentiated Thyroid Carcinoma
Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer
Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
This phase II trial studies how well giving sunitinib malate works in treating patients with iodine-refractory recurrent or metastatic thyroid cancer.
- Conditions
- Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer
- Trial name
- NCT00519896
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Washington
Differentiated Thyroid Cancer
Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)
The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with Differentiated Thyroid Cancer.
- Trial name
- NCT02586337
- Testing
- Anlotinib
- Where
- 19 sites in China
- Volunteers
- 113 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
This phase II trial studies how well sunitinib malate works in treating patients with thyroid cancer that did not respond to iodine I 131 (radioactive iodine) and cannot be removed by surgery.
- Conditions
- Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma AJCC v7
- Trial name
- NCT00381641
- Testing
- Laboratory Biomarker Analysis, Pharmacogenomic Study, Sunitinib
- Where
- 17 sites in United States
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Neoplasm of Thyroid, Heart Diseases
Thyrotropin Over-suppression and Heart
The investigators evaluated the cardiac effects of Thyroid-stimulating hormone (TSH) over-suppression in women with differentiated thyroid cancer (DTC) frequently encountered during suppression therapy.
- Conditions
- Malignant Neoplasm of Thyroid, Heart Diseases, Thyrotoxicosis on Thyroxine Therapy
- Trial name
- NCT02645786
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Chuncheon Sacred Heart Hospital
Thyroid Cancer
ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer
Prospective randomized open phase III non-inferiority trial in cT1bT2N0 papillary thyroid carcinoma comparing: total thyroidectomy alone (experimental group) versus total thyroidectomy + Prophylactic Neck Dissection PND…
- Trial name
- ESTIMABL3 (NCT03570021)
- Testing
- total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection, total thyroidectomy alone without neck dissection
- Where
- 21 sites in France, Guadeloupe and 1 more
- Volunteers
- 352 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Thyroid Cancer
Study of External Beam Radiotherapy to Thyroid Carcinoma
The primary objective of this study is to estimate the 5 year locoregional control rate after External Beam Radiotherapy (EBRT) in the patient with locally advanced differentiated thyroid cancer.
- Trial name
- NCT01173289
- Testing
- External Beam Radiotherapy
- Where
- South Korea
- Volunteers
- 62 people
- Sponsor
- National Cancer Center, Korea
Advanced Differentiated Thyroid Gland Carcinoma
COACH - Comparing Two Different Methods to Suppress Thyrotropin in Patients With Advanced Thyroid Cancer
Most thyroid cancers can be cured with surgery, sometimes with radioactive iodine therapy. However, some patients have cancer that has spread, and some have cancer that comes back after treatment.
- Trial name
- NCT06790589
- Testing
- Levothyroxine Oral Tablet [Synthroid]
- Volunteers
- 70 people
- Sponsor
- AHS Cancer Control Alberta
Differentiated Thyroid Cancer
Radiofrequency in Differentiated Thyroid Cancer Metastatic Lymph Node: Prospective Study of Safety and Efficacy
Radiofrequency (RF) could be technically feasible and effective in the treatment of lymph node metastases of differentiated thyroid cancer.
- Trial name
- METATHYRAF (NCT03416686)
- Testing
- Radiofrequency (RF star electrode electrode_Fixed)
- Where
- 3 sites in France
- Volunteers
- 14 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Thyroid Neoplasms, Differentiated Thyroid Cancer
PET Evaluation of Recurrent Differentiated Thyroid Cancer
After initial treatment of differentiated thyroid cancer patients (DTC) are followed by a blood test, a biomarker called thyroglobulin, in order to detect a possible recurrence.
- Trial name
- THYROPET (NCT01641679)
- Where
- 15 sites in Netherlands
- Volunteers
- 100 people
- Sponsor
- The Netherlands Cancer Institute
Thyroid Neoplasm
A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin
Background: Patients who have advanced thyroid cancer have a low long-term survival rate. These types of thyroid cancer do not respond well to conventional surgery or radiation, or to specific thyroid cancer treatments such as…
- Trial name
- NCT01182285
- Testing
- Valproic Acid, Liothyronine Sodium
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Thyroid Cancer
Study of Apatinib in Patients With Differentiated Thyroid Cancer
The purpose of this study is to assess the efficacy and safety of apatinib in locally advanced/metastatic radioactive iodine-refractory/resistant differentiated thyroid cancer
- Trial name
- NCT02731352
- Testing
- Apatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Lymph Node Dissection, Lymph Node Metastases
Significance of Contralateral Central Lymph Node Dissection in Unilateral cN0 Differentiated Thyroid Carcinoma.
There are so many contradictions over central lymph node dissection in unilateral cN0(Clinically N0) differentiated thyroid carcinoma.In order to provides a new theoretical basis for the operation of central lymph node in…
- Conditions
- Lymph Node Dissection, Lymph Node Metastases, Differentiated Thyroid Carcinoma
- Trial name
- NCT03845647
- Testing
- contralateral central lymph node dissection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
This phase II trial tests how well vemurafenib and cobimetinib work in treating patients with high risk differentiated thyroid carcinoma with BRAFV600E mutation, in preparation for radioactive iodine therapy.
- Conditions
- Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma
- Trial name
- NCT06440850
- Testing
- Biospecimen Collection, Cobimetinib, Computed Tomography
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- City of Hope Medical Center
Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
This phase II trial studies the effect of selpercatinib given before surgery in treating patients with thyroid cancer whose tumors have RET alterations (changes in the genetic material [deoxyribonucleic acid (DNA)]).
- Conditions
- Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Thyroid Gland Anaplastic Carcinoma
- Trial name
- NCT04759911
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Selpercatinib
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer
Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer
RATIONALE: Celecoxib may stop the growth of thyroid cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth.
- Trial name
- NCT00061906
- Testing
- celecoxib
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer
Sacituzumab govitEcan in THYroid Cancers
SETHY is a prospective, multicohort, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory differentiated…
- Trial name
- SETHY (NCT06235216)
- Testing
- Sacituzumab govitecan
- Where
- 11 sites in Spain
- Volunteers
- 42 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Thyroid Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to compare the progression free survival, overall response rate (ORR) and safety of participants treated with lenvatinib 24 mg by continuous once…
- Trial name
- SELECT (NCT01321554)
- Testing
- Lenvatinib
- Where
- 155 sites in United States, Argentina and 21 more
- Volunteers
- 392 people
- Sponsor
- Eisai Inc.
Thyroid Neoplasms
An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors
The purpose of the study was to assess the use of Multikinase Inhibitors (MKIs) in the treatment of patients with a progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAI) who do not have any…
- Trial name
- RIFTOS MKI (NCT02303444)
- Testing
- Sorafenib (Nexavar, BAY43-9006), Other Multikinase inhibitors
- Where
- 34 sites in United States, Algeria and 17 more
- Volunteers
- 667 people
- Sponsor
- Bayer
Differentiated Thyroid Cancer, Lymph Node Metastases
Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma
Background: Despite a favorable prognosis, metastatic cervical lymph nodes (LN), are not uncommon among patients with differentiated thyroid cancer (DTC).
- Trial name
- NCT05078853
- Testing
- Point of care assay for thyroglobulin (POC-Tg) evaluation of a suspected cervical lymph node
- Where
- 5 sites in Israel
- Volunteers
- 250 people
- Sponsor
- Soroka University Medical Center
Differentiated Thyroid Cancer, Osteoporosis
99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis
Postmenopausal women with differentiated thyroid cancer (DTC) taking suppressive doses of levothyroxine (L-T4) are thought to have accelerated bone loss and increased risk of osteoporosis.
- Trial name
- NCT02304757
- Testing
- 99Tc-MDP, Fosamax
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine